Shares of Icon Plc (NASDAQ:ICLR) have received a consensus rating of “Buy” from the eleven research firms that are covering the firm, Marketbeat.com reports. Two analysts have rated the stock with a sell rating, one has assigned a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $149.00.
Several equities analysts have recently commented on ICLR shares. BidaskClub lowered Icon from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, August 21st. Zacks Investment Research upgraded Icon from a “hold” rating to a “buy” rating and set a $163.00 price objective on the stock in a research report on Thursday, August 9th. Robert W. Baird reiterated a “buy” rating and set a $154.00 price objective on shares of Icon in a research report on Thursday, July 26th. SunTrust Banks increased their price objective on Icon to $153.00 and gave the company a “buy” rating in a research report on Thursday, July 26th. Finally, Mizuho set a $146.00 price objective on Icon and gave the company a “hold” rating in a research report on Monday, August 6th.
A number of institutional investors and hedge funds have recently bought and sold shares of ICLR. WCM Investment Management CA grew its position in Icon by 7.9% during the 3rd quarter. WCM Investment Management CA now owns 5,000,711 shares of the medical research company’s stock worth $768,860,000 after acquiring an additional 367,131 shares during the last quarter. Partner Fund Management L.P. lifted its holdings in Icon by 61.1% in the 2nd quarter. Partner Fund Management L.P. now owns 432,312 shares of the medical research company’s stock worth $57,294,000 after buying an additional 163,959 shares during the period. Principal Financial Group Inc. lifted its holdings in Icon by 20.6% in the 1st quarter. Principal Financial Group Inc. now owns 946,806 shares of the medical research company’s stock worth $111,856,000 after buying an additional 161,558 shares during the period. Advisors Asset Management Inc. lifted its holdings in Icon by 3,097.7% in the 2nd quarter. Advisors Asset Management Inc. now owns 153,202 shares of the medical research company’s stock worth $650,000 after buying an additional 148,411 shares during the period. Finally, Redwood Investments LLC purchased a new stake in Icon in the 2nd quarter worth approximately $16,964,000. Institutional investors and hedge funds own 87.62% of the company’s stock.
Shares of NASDAQ:ICLR traded down $0.67 on Monday, hitting $138.46. The company’s stock had a trading volume of 155,402 shares, compared to its average volume of 260,155. Icon has a 1 year low of $101.22 and a 1 year high of $155.33. The stock has a market cap of $7.77 billion, a P/E ratio of 25.69, a PEG ratio of 2.06 and a beta of 0.50. The company has a quick ratio of 2.17, a current ratio of 2.17 and a debt-to-equity ratio of 0.26.
Icon (NASDAQ:ICLR) last released its quarterly earnings results on Wednesday, October 24th. The medical research company reported $1.54 earnings per share for the quarter, meeting the consensus estimate of $1.54. The firm had revenue of $655.02 million for the quarter, compared to analysts’ expectations of $654.66 million. Icon had a return on equity of 26.08% and a net margin of 12.88%. On average, equities research analysts expect that Icon will post 6.08 EPS for the current fiscal year.
ICON Public Limited Company, a clinical research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the United States, and internationally. It specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.
Recommended Story: What is a put option?
Receive News & Ratings for Icon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon and related companies with MarketBeat.com's FREE daily email newsletter.